Matches in SemOpenAlex for { <https://semopenalex.org/work/W2255616997> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2255616997 endingPage "e17502" @default.
- W2255616997 startingPage "e17502" @default.
- W2255616997 abstract "e17502 Background: Capecitabine is an oral fluoropyrimidine used to treat patients with metastatic colorectal cancer (mCRC). Recent trials in 1 st - and 2 nd -line treatment have shown that capecitabine in combination with oxaliplatin (XELOX) is non-inferior to FOLFOX4 in terms of progression-free survival, overall survival and response rates. XELOX offers patients the advantage of treatment every 3 weeks rather than every 2 weeks without the need for lengthy infusions. This analysis evaluated the cost- effectiveness of replacing FOLFOX4 with XELOX for 1 st - and 2 nd -line treatment of mCRC from both Canadian healthcare system payor and societal perspectives. Methods: Based on evidence of non-inferiority of XELOX vs. FOLFOX4, cost-minimization analyses (CMA) were conducted using phase III clinical trial data. The CMA compared total cost associated with chemotherapy medications, administration of chemotherapy, and treatment related toxicities. For the societal perspective, patients’ costs and time were also included. The costs (or savings) were compared for 1 st -line XELOX vs. FOLFOX4 and 2 nd -line XELOX vs. FOLFOX4. Due to variation in Canadian clinical practice, sensitivity analyses using the FOLFOX6 regimen as a comparator were performed. Results: Cost savings per patient for XELOX vs. FOLFOX4 from a healthcare system payor perspective and a societal perspective are shown in the Table . XELOX was also associated with cost savings when compared with the simplified administration regimen of FOLFOX6. Reduced costs for chemotherapy administration and costs for patients’ time and travel primarily related to fewer clinic visits offset the increased drug acquisition cost of the XELOX regimen. Conclusions: Replacing FOLFOX with XELOX is associated with cost savings from the healthcare system payor and societal perspectives while preserving clinical efficacy. [Table: see text] [Table: see text]" @default.
- W2255616997 created "2016-06-24" @default.
- W2255616997 creator A5010785367 @default.
- W2255616997 creator A5015429476 @default.
- W2255616997 creator A5023500477 @default.
- W2255616997 creator A5026035409 @default.
- W2255616997 creator A5041458165 @default.
- W2255616997 date "2009-05-20" @default.
- W2255616997 modified "2023-09-26" @default.
- W2255616997 title "Cost-effectiveness of capecitabine in combination with oxaliplatin (XELOX) compared with FOLFOX for the treatment of metastatic colorectal cancer: A Canadian evaluation" @default.
- W2255616997 doi "https://doi.org/10.1200/jco.2009.27.15_suppl.e17502" @default.
- W2255616997 hasPublicationYear "2009" @default.
- W2255616997 type Work @default.
- W2255616997 sameAs 2255616997 @default.
- W2255616997 citedByCount "0" @default.
- W2255616997 crossrefType "journal-article" @default.
- W2255616997 hasAuthorship W2255616997A5010785367 @default.
- W2255616997 hasAuthorship W2255616997A5015429476 @default.
- W2255616997 hasAuthorship W2255616997A5023500477 @default.
- W2255616997 hasAuthorship W2255616997A5026035409 @default.
- W2255616997 hasAuthorship W2255616997A5041458165 @default.
- W2255616997 hasConcept C112930515 @default.
- W2255616997 hasConcept C121608353 @default.
- W2255616997 hasConcept C126322002 @default.
- W2255616997 hasConcept C143998085 @default.
- W2255616997 hasConcept C2776694085 @default.
- W2255616997 hasConcept C2777909004 @default.
- W2255616997 hasConcept C2778260052 @default.
- W2255616997 hasConcept C2780456651 @default.
- W2255616997 hasConcept C2780962732 @default.
- W2255616997 hasConcept C2781413609 @default.
- W2255616997 hasConcept C3019080777 @default.
- W2255616997 hasConcept C526805850 @default.
- W2255616997 hasConcept C71924100 @default.
- W2255616997 hasConceptScore W2255616997C112930515 @default.
- W2255616997 hasConceptScore W2255616997C121608353 @default.
- W2255616997 hasConceptScore W2255616997C126322002 @default.
- W2255616997 hasConceptScore W2255616997C143998085 @default.
- W2255616997 hasConceptScore W2255616997C2776694085 @default.
- W2255616997 hasConceptScore W2255616997C2777909004 @default.
- W2255616997 hasConceptScore W2255616997C2778260052 @default.
- W2255616997 hasConceptScore W2255616997C2780456651 @default.
- W2255616997 hasConceptScore W2255616997C2780962732 @default.
- W2255616997 hasConceptScore W2255616997C2781413609 @default.
- W2255616997 hasConceptScore W2255616997C3019080777 @default.
- W2255616997 hasConceptScore W2255616997C526805850 @default.
- W2255616997 hasConceptScore W2255616997C71924100 @default.
- W2255616997 hasIssue "15_suppl" @default.
- W2255616997 hasLocation W22556169971 @default.
- W2255616997 hasOpenAccess W2255616997 @default.
- W2255616997 hasPrimaryLocation W22556169971 @default.
- W2255616997 hasRelatedWork W145440300 @default.
- W2255616997 hasRelatedWork W1997133872 @default.
- W2255616997 hasRelatedWork W2008622172 @default.
- W2255616997 hasRelatedWork W2075077394 @default.
- W2255616997 hasRelatedWork W2292524700 @default.
- W2255616997 hasRelatedWork W2375984193 @default.
- W2255616997 hasRelatedWork W2380684846 @default.
- W2255616997 hasRelatedWork W2417717847 @default.
- W2255616997 hasRelatedWork W2539385516 @default.
- W2255616997 hasRelatedWork W3041595120 @default.
- W2255616997 hasVolume "27" @default.
- W2255616997 isParatext "false" @default.
- W2255616997 isRetracted "false" @default.
- W2255616997 magId "2255616997" @default.
- W2255616997 workType "article" @default.